Compare Infosys Limited (INFY) vs Novavax Inc (NVAX) Price & Performance

INFY trades at $12.215, down 2.75% today, with mixed technical signals showing a bullish moving average trend but bearish oscillators including RSI above 76. Fundamentally, the company maintains strong profitability with 16.37% net margins and 32.12% ROE, though Q2 2026 earnings missed expectations. Recent news highlights strategic AI collaborations with Metsä Group and Sentara Healthcare while Q1 2027 results showed revenue challenges but margin resilience.

The outlook remains cautious with analyst consensus at Hold (55%) and $11.05 price target below current levels. Key opportunities include growing AI revenue streams and strong cash flow generation, while risks involve revenue growth volatility and competitive IT services market pressures. The stock faces near-term headwinds from lowered growth guidance but maintains solid fundamentals.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.